Sg Americas Securities, LLC Adaptimmune Therapeutics PLC Transaction History

Sg Americas Securities, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 07, 2022	SELL	$3.5 - $5.68 $298,070 - $483,725	-85,163 Closed	0 $0
Q3 2021 Nov 01, 2021	SELL	$3.44 - $6.37 $517,895 - $959,009	-150,551 Reduced 63.87%	85,163 $440,000
Q2 2021 Aug 12, 2021	BUY	$3.86 - $5.78 $3,142 - $4,704	814 Added 0.35%	235,714 $1 Million
Q1 2021 May 13, 2021	BUY	$4.9 - $6.83 $1.15 Million - $1.6 Million	234,900 New	234,900 $1.25 Million
Q4 2019 Jan 28, 2020	SELL	$0.72 - $1.43 $15,830 - $31,441	-21,987 Closed	0 $0
Q3 2019 Nov 04, 2019	SELL	$1.43 - $3.81 $1,818 - $4,846	-1,272 Reduced 5.47%	21,987 $33,000
Q2 2019 Jul 29, 2019	BUY	$3.23 - $5.41 $15,348 - $25,708	4,752 Added 25.68%	23,259 $94,000
Q1 2019 Apr 29, 2019	SELL	$3.63 - $6.06 $5,434 - $9,071	-1,497 Reduced 7.48%	18,507 $80,000
Q4 2018 Feb 01, 2019	BUY	$3.76 - $14.16 $45,981 - $173,162	12,229 Added 157.29%	20,004 $115,000
Q3 2018 Nov 06, 2018	SELL	$8.27 - $13.56 $108,527 - $177,947	-13,123 Reduced 62.8%	7,775 $105,000
Q2 2018 Aug 07, 2018	SELL	$10.42 - $13.74 $4,126 - $5,441	-396 Reduced 1.86%	20,898 $248,000
Q1 2018 May 03, 2018	BUY	$7.1 - $11.56 $151,187 - $246,158	21,294 New	21,294 $239,000

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $101M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.